trial
-
Spine
SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) — SPR Therapeutics, a private medical device company focused on treating pain and improving…
Read More » -
Biologics
Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH
SCHLIEREN (ZURICH), Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences, a leader in next generation bone graft technologies, today announced…
Read More » -
Sports Medicine
Stem cell therapy trial at Sanford first of its kind in U.S. for shoulder injuries
SIOUX FALLS, S.D. – The first FDA-approved clinical trial of its kind in the United States using a person’s own…
Read More » -
Biologics
SpinalCyte, LLC Receives Institutional Review Board Approval for Phase I Clinical Trial
December 13, 2016 HOUSTON–(BUSINESS WIRE)–SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus…
Read More » -
Spine
Stryker Conducts Successful Pre-Clinical Trial on 3D Printed Tritanium PL Interbody Cage
by Tyler Koslow | Nov 2, 2016 When it comes to utilizing 3D printing technology to produce medical devices and…
Read More » -
Biologics
Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury Patient with Maximum Dose of AST-OPC1 in SCiStar Clinical Trial
FREMONT, Calif., Nov. 8, 2016 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine,…
Read More » -
Neuro
Mainstay Medical ReActiv8-A sustains performance at one year in clinical trial
27th September 2016 Mainstay Medical has announced the one-year results from the ReActiv8-A Clinical Trial, an international, multi-centre, prospective, single…
Read More » -
Hospitals
Regentis Receives IDE Approval for Pivotal GelrinC Clinical Trial
Princeton, NJ and Or Akiva, Israel, September 26 — Regentis Biomaterials, a developer of hydrogels for tissue regeneration, announced it…
Read More » -
Neuro
Trial offers hope of a treatment for spinal muscular atrophy
September 20, 2016 – University of Oxford SMA occurs when people lack a gene called survival motor neuron 1 (SMN1). It…
Read More » -
Neuro
Asterias Biotherapeutics Receives Safety Clearance to Begin Administering the Highest Dose of AST-OPC1 in the SCiStar Phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients
FREMONT, Calif., Aug. 31, 2016 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of…
Read More » -
Hospitals
CollPlant Reports Positive Final Extended Clinical Trial Results with Vergenix™STR for Treatment of Tendinopathy
Ness Ziona, Israel, August 17, 2016 – CollPlant Ltd. (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen…
Read More » -
Spine
SI-BONE, Inc. Announces Two-Year Results from a Randomized Controlled Trial of the iFuse Implant System® vs. Non-Surgical Management for Some Causes of Sacroiliac Joint Dysfunction
SAN JOSE, Calif., Aug. 24, 2016 /PRNewswire/ — SI-BONE, Inc., a medical device company that pioneered the use of the iFuse…
Read More » -
Hospitals
Jury Sides with Surgeon in Bone Cement Trial
AUGUST 16, 2016 SEATTLE (AP) – A jury has found in favor of a University of Washington surgeon who was…
Read More » -
Biologics
Grafix® Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon and Bone Clinical Trial is Available Electronically in Peer-Reviewed Journal
COLUMBIA, Md., Aug. 04, 2016 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular regenerative medicine company focused on…
Read More » -
Spine
Mesoblast’s Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science
MELBOURNE, Australia and NEW YORK, Aug. 01, 2016 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the 24-month…
Read More »